Janux Therapeutics, Inc. Common Stock
$16.59
-$0.27 (-1.60%)
$16.40Day Range$16.86
Key Statistics
Market Cap
$1.01B
Shares Outstanding
61.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 11, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$16.70
Day High
$16.86
Day Low
$16.40
Volume
2.45M
VWAP
$16.59
Prev Close
$16.86
Transactions
--
Acc. Volume
--
About Janux Therapeutics, Inc. Common Stock
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
PHARMACEUTICAL PREPARATIONSSIC 2834113 employees10955 VISTA SORRENTO PARKWAY, SAN DIEGO, CA, 92130(858) 751-4493IPO Jun 11, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001817713
- Composite FIGI
- BBG00ZHSKH11
- Share Class FIGI
- BBG00ZHSKH39
- Ticker Root
- JANX
- SIC Code
- 2834
About Janux Therapeutics, Inc. Common Stock (JANX) Stock
Janux Therapeutics, Inc. Common Stock (JANX) closed the 2026-09-18 session at $16.59, down 1.60% versus the previous close (-0.27). The stock opened at $16.70 and traded between $16.40 and $16.86 during that session. Session trading volume was 2.4M shares. The volume-weighted average price (VWAP) is $16.59.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Janux Therapeutics, Inc. Common Stock has a market capitalization of $1.01 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. JANX is listed on the XNAS exchange. The company employs approximately 113 people. Janux Therapeutics, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2021-06-11.
On this page you can find market JANX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.